The conclusion drawn from the study was that PD-L1 is used by cancer cells to inhibit the immune system, and with the influence of hypoxia upon PD-L1 expression, the tumour becomes more aggressive requiring anti-PD-L1 targeted therapy for its management [46]. The gene discussed is CD274; the disease is cancer.